- MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
- MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
- MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
- MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
- MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
- MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
- MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
- MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
- MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
More ▼
Key statistics
On Wednesday, MoonLake Immunotherapeutics (MLTX:NAQ) closed at 42.20, 20.19% above the 52 week low of 35.11 set on Nov 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.03 |
---|---|
High | 42.83 |
Low | 39.91 |
Bid | 39.28 |
Offer | 45.88 |
Previous close | 40.15 |
Average volume | 400.48k |
---|---|
Shares outstanding | 63.87m |
Free float | 53.27m |
P/E (TTM) | -- |
Market cap | 2.56bn USD |
EPS (TTM) | -0.7501 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼